The Food and Drug Administration just dealt a crushing setback to patients living with Duchenne muscular dystrophy.

Last week, the FDA’s advisory committee voted 9–3 that the evidence was insufficient to establish the effectiveness of Deramiocel, Capricor Therapeutics’ treatment for a heart condition associated with DMD. That decision will stand, and patients will suffer and die, unless it is reversed by Aug. 22. 

Recommended Stories

Americans with terminal diseases won’t survive more FDA delays

The FDA stacked a panel with peptide sellers. Guess what it voted to greenlight

Stop forcing vets abroad: Trump’s FDA is bringing a game-changing PTSD treatment home